Infections are a major cause of death in patients treated with CAR T-cell therapy Meta-analysis focused on causes of death, excluding relapse, recurrence

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.

November 15, 2024

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

November 15, 2024

Vol.50 No.43

Clinical Roundup

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Researchers from the USC Norris Comprehensive Cancer Center found evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases. The study has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal cancer.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Wugen launches phase II study of CD7-targeted CAR T for r/r T-ALL or T-ALL/LBL

Wugen Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, announced it will initiate a phase II study in the first quarter of 2025 for the company’s potential first-in-class, investigational, anti-CD7 CAR T-cell therapy, WU-CART-007, in patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.

November 15, 2024

Vol.50 No.43

In Brief

Thomas Bradley named director of hematology and oncology at Northwell’s Florina Cancer Center

Thomas Bradley has been appointed director of hematology and oncology at Staten Island University Hospital’s Florina Cancer Center to spearhead the division’s clinical, educational, and research initiatives.

October 25, 2024

Vol.50 No.40

In Brief

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation awarded a $1 million grant to support research at Vanderbilt aimed at dramatically expanding the efficacy of immunotherapy for colorectal cancer.

October 04, 2024

Vol.50 No.37

Infections are a major cause of death in patients treated with CAR T-cell therapy

Meta-analysis focused on causes of death, excluding relapse, recurrence

YOU MAY BE INTERESTED IN

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Wugen launches phase II study of CD7-targeted CAR T for r/r T-ALL or T-ALL/LBL

Thomas Bradley named director of hematology and oncology at Northwell’s Florina Cancer Center

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

Renew today!

Subscriber content

Never miss an issue!

Login